President Biden recently announced that the United States will have enough vaccine doses by the end of May for each adult in America. This is two months earlier than originally thought possible.
What does this new deadline mean for manufacturers, raw material providers, production and packaging teams? How will the government work with private industry to ensure this goal is met?
Manufacturers have been operating at an expedited production schedule for the past year to produce medical products, PPE, goods used daily for home use, and several approved vaccines.
What are the lessons learned in the past year while operating on constant escalated timelines? How are biopharmaceutical manufacturers prioritizing vaccines and continuing to produce other medicines at the same time? And what can traditional manufacturing competitors stepping in to fulfill vaccine production quotas teach us about cooperation in the name of common good?
The Hill will sit down with government leaders, manufacturing and vaccine production experts to discuss how the manufacturing community and their related industries will use what they learned in 2020 to tackle the public health emergencies of the future.
Thursday, March 25
1:00 PM ET/10:00 AM PT
Rep. Jackie Walorski (R-IN), Member, Ways & Means Committee; Member, Manufacturing Caucus Dr. Simone Blayer, Global Head of Chemistry, Manufacturing & Control, Center for Vaccine Innovation and Access, PATH Sean Kirk, EVP, Manufacturing & Technical Operations, Emergent BioSolutions Cody Powers, Principal, ZS Associates Dr. José R. Romero, MD, FAAP, Chair, Advisory Committee on Immunization Practices Committee, CDC; Secretary, Dept. of Health, Arkansas
Additional speakers to be announced.
Steve Clemons, Editor-at-Large, The Hill